Project Grant R37CA306402
Award Date 8/25/25
Completion Date 7/31/30
Dollars Obligated $659K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $703,321 Cooperative Agreement on September 8, 2025 to Kaiser Foundation Hospitals under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award will support the adaptation and implementation of an evidence-based patient navigation intervention for adolescent and young adult (AYA) cancer survivors over a 2-year project period ending August 31, 2027. The project aims to improve coordination of care, including surveillance for...
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- The National Cancer Institute (NCI) awarded a $858,166 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The General Hospital Corporation (Massachusetts General Hospital) to conduct a randomized trial of a targeted palliative care intervention for patients with metastatic breast cancer. The study aims to improve documentation of end-of-life care preferences, delivery of end-of-life care, and patient-reported outcomes for this vulnerable population. The project...
- This $680,507 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395). The grant aims to elucidate the mechanisms of cancer "persister cells" and identify druggable targets to eliminate them, with a focus on KRAS-mutant non-small cell lung cancer. Specifically, the grant seeks to: (1) illuminate signals that promote persistence, (2) identify and validate targets that inhibit...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $729,587 to The Regents of the University of California, San Francisco (UCSF) to develop a personalized, voxel-wise prediction model for brain metastases in non-small cell lung cancer adenocarcinoma patients. The research aims to create a patient-specific risk model that integrates population-based, anatomical, vascular, and patient treatment history data to predict...
- The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on January 3, 2025, supports a 5-year research project focused on "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to...
- This Cooperative Agreement award of $675,867 from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Cause and Prevention Research" (CFDA 93.393), aims to increase the delivery of practical geriatric assessment in community oncology settings. The goal is to improve outcomes for older adult cancer patients (age 65+) who comprise 75% of the projected 22.2 million U.S. cancer survivors by 2030. The project will compare standard ASCO educational materials...
- The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
- This federal Project Grant award, valued at $130,301 and provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports the extension and leveraging of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The principal investigator, a research associate and core manager of the Biostatistics Shared Resource at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, will utilize their...
- The National Cancer Institute (NCI) awarded a $5,041,790 Cooperative Agreement under the Cancer Centers Support Grants (CFDA 93.397) program to the University of California, San Francisco (UCSF) to improve cancer health disparities. The 5-year project, starting on August 1, 2025, will investigate the interplay of tumor genomic and immune characteristics with individual risk factors and social and structural drivers of health across three diverse cancers: meningioma, prostate cancer, and breast...
The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $658,743 project grant to Kaiser Foundation Hospitals, doing business as Kaiser Permanente. The purpose of this 5-year grant, awarded on Aug 25, 2025, is to develop and validate prediction models for trajectories of function, cognition, and quality of life among adults aged 65 and older with advanced non-small cell lung cancer during chemotherapy and/or immunotherapy treatment. The research will involve a comprehensive prospective evaluation of this patient population to provide vital information to help older adults with advanced lung cancer make informed decisions about their cancer care.
Generated 10/14/25, 5:21 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $658.7k | 8/25/25 |